Robert E. Conway - 03 Jan 2022 Form 4 Insider Report for ALPINE IMMUNE SCIENCES, INC.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 03 Jan 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Jan 2022, 16:31:43 UTC
Prior SEC filing: 27 Sep 2021
Next SEC filing: 19 Dec 2022
Source filing: View source filing
Reporting owner signature: /s/ James Paul Rickey, attorney-in-fact

Key filing fact

Robert E. Conway filed Form 4 for ALPINE IMMUNE SCIENCES, INC. on 04 Jan 2022.

Key facts

This page summarizes Robert E. Conway's Form 4 filing for ALPINE IMMUNE SCIENCES, INC..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 04 Jan 2022, 16:31.

Change

Previous filing in this sequence was filed on 27 Sep 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ALPN transaction Derivative

Stock Option (Right to buy)

Award

Transaction value: $0
Shares: +10,000
Change %
Price: $0.000000
Shares after: 10,000
Date: 03 Jan 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,000
Exercise price: $13.89
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant.

Footnote F2

1/12th of the shares subject to the option become vested and exercisable on February 3, 2022 and 1/12th of the shares subject to the option shall vest monthly thereafter.